Phase I Study of Safety and Persistence of UC-781 Vaginal Microbicide

Inclusion Criteria for Screening Visit: * HIV uninfected * General good health * Normal Pap smear within 12 months prior to screen or obtained at screening visit * Anatomy that lends itself easily to visualization of the cervix * Sexual abstinence (including vaginal, oral, and rectal) from Visit 1 to the completion of Visit 4 * Agree to use condoms provided by the study between Visits 4 and 5 * Agree to abstain from the use of intravaginal products or vaginal penetration throughout the study * Willing to use acceptable forms of contraception until the completion of study * Willing to participate in all study-related assessments and follow all study-related procedures Inclusion Criteria for Study Entry: * Meet all inclusion criteria for the screening visit at Study Entry * Willing to stay in the Magee-Womens Hospital Clinical Research Center (MWH CRC) for up to 9 hours after gel insertion Exclusion Criteria for Screening Visit: * Menopause (at least 12 months without menses in absence of long-acting progestin use) * Hysterectomy * Latex allergy * Use of a diaphragm, NuvaRing, or spermicide for contraception * Diagnosed urogenital infection or suspected infection 21 days prior to study screening. More information on this criterion can be found in the protocol. * Menses or other vaginal bleeding anticipated in the 17 days postscreening * Antibiotic or antifungal therapy (vaginal or systemic) 14 days prior to study screening * Injected nontherapeutic drugs 12 months prior to study screening * Systemic immunosuppressive drug use 60 days prior to study screening * Participation in drug, spermicide, and/or microbicide study 30 days prior to study screening * Any condition that, in the opinion of the investigator, would interfere with the study * Intravaginal use of any device or product (except tampons) 7 days prior to study screening * Surgical procedure involving the pelvis in the 90 days prior to enrollment (e.g., dilation and curettage or evacuation, cervical biopsy, cryosurgery,any other surgery involving pelvic organs or area) * Abnormal pelvic exam finding that, in the opinion of the investigator would complicate interpretation of the colposcopy * Pregnancy, or within 90 days of last pregnancy * Breastfeeding Exclusion Criteria for Study Entry: * Meets any of the exclusion criteria of the screening visit * Diagnosed or suspected reproductive tract infection or urinary tract infection. More information on this criterion can be found in the protocol. * Menses or other vaginal bleeding anticipated in the 8 days following study entry * Injected nontherapeutic drugs between study screening and study entry * Certain abnormal laboratory values